Stock Track | Ardelyx Plunges 10.68% Post-Market on Q4 Earnings Miss and Widening Annual Loss

Stock Track

12 hours ago

Ardelyx Inc. (NASDAQ: ARDX) experienced a significant decline of 10.68% in post-market trading on Thursday. The sharp drop followed the release of the company's fourth-quarter and full-year 2025 financial results.

The biopharmaceutical firm reported quarterly earnings of $0.00 per share, which missed the analyst consensus estimate of $0.01 by a substantial margin. This result also represents a 95% decrease compared to earnings of $0.02 per share from the same period last year. Although quarterly sales of $125.215 million surpassed expectations, investor focus shifted to the disappointing bottom line and a concerning trend in annual profitability.

According to the financial reports, Ardelyx's net loss for the full year 2025 widened to $61.6 million, compared to a net loss of $39.1 million in 2024. This indicates ongoing challenges in achieving profitability despite revenue growth from its key products, IBSRELA and XPHOZAH. The combination of the earnings miss and the expanding annual loss appears to have driven significant selling pressure among investors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1128899259"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128899259\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128899259?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 09:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128899259","market":"nz","top_or_hot":-1,"title":"Stock Track | Ardelyx Plunges 10.68% Post-Market on Q4 Earnings Miss and Widening Annual Loss","media":"Stock Track","content":"<p>Ardelyx Inc. (NASDAQ: ARDX) experienced a significant decline of 10.68% in post-market trading on Thursday. The sharp drop followed the release of the company's fourth-quarter and full-year 2025 financial results.</p><p>The biopharmaceutical firm reported quarterly earnings of $0.00 per share, which missed the analyst consensus estimate of $0.01 by a substantial margin. This result also represents a 95% decrease compared to earnings of $0.02 per share from the same period last year. Although quarterly sales of $125.215 million surpassed expectations, investor focus shifted to the disappointing bottom line and a concerning trend in annual profitability.</p><p>According to the financial reports, Ardelyx's net loss for the full year 2025 widened to $61.6 million, compared to a net loss of $39.1 million in 2024. This indicates ongoing challenges in achieving profitability despite revenue growth from its key products, IBSRELA and XPHOZAH. The combination of the earnings miss and the expanding annual loss appears to have driven significant selling pressure among investors.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ardelyx Plunges 10.68% Post-Market on Q4 Earnings Miss and Widening Annual Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ardelyx Plunges 10.68% Post-Market on Q4 Earnings Miss and Widening Annual Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-20 09:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ardelyx Inc. (NASDAQ: ARDX) experienced a significant decline of 10.68% in post-market trading on Thursday. The sharp drop followed the release of the company's fourth-quarter and full-year 2025 financial results.</p><p>The biopharmaceutical firm reported quarterly earnings of $0.00 per share, which missed the analyst consensus estimate of $0.01 by a substantial margin. This result also represents a 95% decrease compared to earnings of $0.02 per share from the same period last year. Although quarterly sales of $125.215 million surpassed expectations, investor focus shifted to the disappointing bottom line and a concerning trend in annual profitability.</p><p>According to the financial reports, Ardelyx's net loss for the full year 2025 widened to $61.6 million, compared to a net loss of $39.1 million in 2024. This indicates ongoing challenges in achieving profitability despite revenue growth from its key products, IBSRELA and XPHOZAH. The combination of the earnings miss and the expanding annual loss appears to have driven significant selling pressure among investors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARDX","symbol_name":"Ardelyx","start_time":0,"source_url":"","article_id":"1128899259","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128899259","pubTimestamp":1771549741,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ardelyx Inc. (NASDAQ: ARDX) experienced a significant decline of 10.68% in post-market trading on Thursday. The sharp drop followed the release of the company's fourth-quarter and full-year 2025...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARDX":"Ardelyx"},"translate_title":"个股追踪|Ardelyx盘后暴跌10.68%，因第四季度盈利未达预期且年度亏损扩大","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDX":1},"content_text":"Ardelyx Inc. (NASDAQ: ARDX) experienced a significant decline of 10.68% in post-market trading on Thursday. The sharp drop followed the release of the company's fourth-quarter and full-year 2025 financial results.The biopharmaceutical firm reported quarterly earnings of $0.00 per share, which missed the analyst consensus estimate of $0.01 by a substantial margin. This result also represents a 95% decrease compared to earnings of $0.02 per share from the same period last year. Although quarterly sales of $125.215 million surpassed expectations, investor focus shifted to the disappointing bottom line and a concerning trend in annual profitability.According to the financial reports, Ardelyx's net loss for the full year 2025 widened to $61.6 million, compared to a net loss of $39.1 million in 2024. This indicates ongoing challenges in achieving profitability despite revenue growth from its key products, IBSRELA and XPHOZAH. The combination of the earnings miss and the expanding annual loss appears to have driven significant selling pressure among investors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}